HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex.

Abstract
Previously, we found that bis(allixinato)oxovanadium(IV) (VO(alx)(2)) exhibits a potent hypoglycemic activity in type 1-like diabetic mice. Since the enhancement of insulin sensitivity is involved in one of the mechanisms by which vanadium exerts its anti-diabetic effects, VO(alx)(2) was further tested in type 2 diabetes with low insulin sensitivity. The effect of oral administration of VO(alx)(2) was examined in obesity-linked type 2 diabetic KKA(y) mice. Treatment of VO(alx)(2) for 4 weeks normalized hyperglycemia, glucose intolerance, hyperinsulinemia, hypercholesterolemia and hypertension in KKA(y) mice; however, it had no effect on hypoadiponectinemia. VO(alx)(2) also improved hyperleptinemia, following attenuation of obesity in KKA(y) mice. This is the first example in which a vanadium compound improved leptin resistance in type 2 diabetes by oral administration. On the basis of these results, VO(alx)(2) is proposed to enhance not only insulin sensitivity but also leptin sensitivity, which in turn improves diabetes, obesity and hypertension in an obesity-linked type 2 diabetic animal.
AuthorsYusuke Adachi, Yutaka Yoshikawa, Jiro Yoshida, Yukihiro Kodera, Akira Katoh, Jitsuya Takada, Hiromu Sakurai
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 345 Issue 3 Pg. 945-50 (Jul 07 2006) ISSN: 0006-291X [Print] United States
PMID16707105 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Leptin
  • Organometallic Compounds
  • bis(allixinato)oxovanadium(IV)
Topics
  • Animals
  • Diabetes Mellitus, Experimental (drug therapy)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Hypertension (drug therapy)
  • Insulin Resistance
  • Leptin (metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Models, Chemical
  • Obesity (drug therapy)
  • Organometallic Compounds (pharmacology)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: